JP2021533150A - 移植片対宿主病の治療のための組成物 - Google Patents

移植片対宿主病の治療のための組成物 Download PDF

Info

Publication number
JP2021533150A
JP2021533150A JP2021506287A JP2021506287A JP2021533150A JP 2021533150 A JP2021533150 A JP 2021533150A JP 2021506287 A JP2021506287 A JP 2021506287A JP 2021506287 A JP2021506287 A JP 2021506287A JP 2021533150 A JP2021533150 A JP 2021533150A
Authority
JP
Japan
Prior art keywords
antibiotic
substance
gvhd
adsorbent
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506287A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020030593A5 (https=
JP2021533150A5 (https=
Inventor
ジャン・ドゥ・ギュンツブルク
Original Assignee
ダ・ヴォルテッラ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダ・ヴォルテッラ filed Critical ダ・ヴォルテッラ
Publication of JP2021533150A publication Critical patent/JP2021533150A/ja
Publication of JPWO2020030593A5 publication Critical patent/JPWO2020030593A5/ja
Publication of JP2021533150A5 publication Critical patent/JP2021533150A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021506287A 2018-08-05 2019-08-05 移植片対宿主病の治療のための組成物 Pending JP2021533150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187409 2018-08-05
EP18187409.0 2018-08-05
PCT/EP2019/071026 WO2020030593A1 (en) 2018-08-05 2019-08-05 Compositions for the treatment of graft versus host disease

Publications (3)

Publication Number Publication Date
JP2021533150A true JP2021533150A (ja) 2021-12-02
JPWO2020030593A5 JPWO2020030593A5 (https=) 2022-06-27
JP2021533150A5 JP2021533150A5 (https=) 2022-06-27

Family

ID=63165229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506287A Pending JP2021533150A (ja) 2018-08-05 2019-08-05 移植片対宿主病の治療のための組成物

Country Status (11)

Country Link
US (1) US20210290741A1 (https=)
EP (1) EP3829552A1 (https=)
JP (1) JP2021533150A (https=)
KR (1) KR20210040395A (https=)
CN (1) CN112689506A (https=)
AU (1) AU2019320483A1 (https=)
BR (1) BR112021002105A2 (https=)
CA (1) CA3106433A1 (https=)
IL (1) IL280589A (https=)
MX (1) MX2021001393A (https=)
WO (1) WO2020030593A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532162A (ja) * 2019-05-06 2022-07-13 シンセティック・バイオロジクス・インコーポレイテッド 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
MX340822B (es) 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
CN107148473B (zh) * 2014-10-08 2021-08-06 合成生物制品有限公司 β-内酰胺酶制剂及其用途
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
CA3254897A1 (en) * 2014-11-25 2026-03-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF APPLIED MICROBIOLOGY, vol. 123, JPN7023002632, 2017, pages 66 - 79, ISSN: 0005263388 *
PHARMACOLOGICAL RESEARCH, vol. 122, JPN6023028388, 2017, pages 90 - 95, ISSN: 0005263389 *
THE JOURNAL OF INFECTIOUS DISEASES, vol. 217, JPN7023002631, February 2018 (2018-02-01), pages 628 - 636, ISSN: 0005263387 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532162A (ja) * 2019-05-06 2022-07-13 シンセティック・バイオロジクス・インコーポレイテッド 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物

Also Published As

Publication number Publication date
CN112689506A (zh) 2021-04-20
US20210290741A1 (en) 2021-09-23
KR20210040395A (ko) 2021-04-13
BR112021002105A2 (pt) 2021-06-01
MX2021001393A (es) 2021-04-12
IL280589A (en) 2021-03-25
CA3106433A1 (en) 2020-02-13
AU2019320483A1 (en) 2021-02-18
EP3829552A1 (en) 2021-06-09
WO2020030593A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
JP4908420B2 (ja) 膵機能不全を治療するための、リパーゼ、プロテアーゼおよびアミラーゼを含有する組成物
JP2020530493A (ja) 腸内の抗生物質耐性菌を除菌するための組成物及び方法
RS54991B1 (sr) Formulacije za oralnu isporuku adsorbenata u creva
EP0671942A1 (en) Medical use, a medical method and a pharmaceutical preparation
WO2004017925A2 (en) Methods and reagents for preventing bacteremias
JP2022106877A (ja) 経口抗生物質からのマイクロバイオーム防御
US11129811B2 (en) Methods and compositions to prevent or treat bacterial infections
JP2026035819A (ja) 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物
JP2021533150A (ja) 移植片対宿主病の治療のための組成物
WO2016059341A1 (fr) Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
JP2021534091A (ja) 抗がん剤の有効性を改善する方法
JPH10127281A (ja) Ｐｅｇ修飾アルギン酸リアーゼおよびその用途
HK40096554A (zh) 一种治疗耐碳青霉烯肺炎克雷伯氏菌感染的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240219